Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meloxicam injection - Recro Pharma

Drug Profile

Meloxicam injection - Recro Pharma

Alternative Names: N-1539; NanoCrystal® meloxicam

Latest Information Update: 14 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Drug Delivery Inc
  • Developer Recro Pharma
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative pain

Most Recent Events

  • 10 Dec 2018 Recro Pharma released safety data of ex vivo assessment, effects of meloxicam IV on platelet function
  • 07 Nov 2018 Recro Pharma announces intention to launch meloxicam for Postoperative pain in USA during the first half of 2019 (IV)
  • 08 Oct 2018 US FDA accepts Recro's Complete Response to the Complete Response Letter through the resubmitted New Drug Application (NDA) for meloxicam in Post operative pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top